Medicure And Reliance Shake Hands On Cardiovascular Biosimilar

Indian Firm Has Xolair Rival

 
• By Dean Rudge

Medicure will take responsibility for gaining approval for an unnamed cardiovascular biosimilar that it has just agreed to license from India’s Reliance Life Sciences in the US, Canada and the EU.

Lungs
Medicure has identified cardiovascular as its primary focus • Source: Shutterstock

More from Biosimilars

More from Products